Bold statement: a seemingly convenient pill form of Ozempic and Wegovy may carry unexpected risks hidden in its delivery helper. And this is the part most people miss: the daily pill relies on a compound called salcaprozate sodium (SNAC) to get semaglutide through the stomach, which could influence more than just the intended weight-loss effects.
The active ingredient in Ozempic and Wegovy has traditionally been given by weekly injections into the fatty tissue beneath the skin of the abdomen, thigh, or upper arm. Now, in response to needle aversion, manufacturers are offering an oral semaglutide pill that aims to mimic the benefits without injections. Wegovy’s pill hit the market in early January, and Ozempic’s pill is anticipated to follow in the spring.
Orally delivered semaglutide works differently from the injectable form because SNAC helps the drug survive the harsh stomach environment and reach the bloodstream. To explore what long-term, repeated exposure to SNAC might do, researchers at the University of Adelaide conducted a 21-day study looking at gut health, metabolism, and related markers.
Lead author Amin Ariaee, a PhD candidate, stresses the balance between pain-free administration and potential side effects. “These medicines are highly effective and are helping many people, but as oral versions become more widely used, we need to understand what repeated, long-term exposure to all ingredients in the pill means for the body—not just the active drug,” he notes.
The study’s key findings over three weeks include:
- A decrease in beneficial gut bacteria that help break down dietary fiber
- Lower levels of short-chain fatty acids, which support the intestinal barrier, curb inflammation, and assist immune function
- Elevated inflammatory markers in the blood
- Increased liver weight
- A reduced cecum, the part of the large intestine where gut bacteria process fiber and generate protective compounds
- Reduced levels of a protein linked to cognitive impairment
Ariaee points out that the convenience of a tablet comes with its own set of consequences. “While SNAC enables oral delivery, our results show shifts in potentially harmful gut bacteria, heightened inflammatory markers, and depletion of proteins connected to cognitive health,” he explains. While the researchers caution that SNAC isn’t proven to be harmful to humans, they emphasize that it affects the body beyond enabling semaglutide’s function and that more research is needed.
Even as Novo Nordisk’s semaglutide pill is already available, a separate daily pill from Eli Lilly, Orforglipron, is expected to gain FDA approval this spring. Both pills come with gastrointestinal side effects and may not deliver the same dramatic weight-loss results seen with injections, but manufacturers remain optimistic about the potential.
In addition to the needle-free appeal, oral pills offer easier storage and shipping, since they don’t require refrigeration like some other GLP-1 therapies. As pills become more convenient and potentially cheaper, experts argue that understanding the effects of consistent SNAC exposure becomes increasingly important for patients who may take these medications daily for long periods.
Senior Research Fellow Dr. Paul Joyce emphasizes this broader view: as usage expands globally, it’s crucial to evaluate every component of these therapies, not just the active drug. Is the trade-off for convenience worth potential gut and cognitive implications over time? What are your thoughts on these oral GLP-1 options and their long-term safety? Share your perspective in the comments.
